Reference : Pharma-clinics le medicament du mois. L'orlistat (xenical).
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Endocrinology, metabolism & nutrition
Pharma-clinics le medicament du mois. L'orlistat (xenical).
[fr] Pharmacy-clinics medication of the month. Orlistate (xenical)
Scheen, André mailto [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Ernest, Philippe mailto [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]
Letiexhe, Michel [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]
Revue Médicale de Liège
Hopital de Baviere
Yes (verified by ORBi)
[en] Dietary Fats/metabolism ; Enzyme Inhibitors/administration & dosage/pharmacology/therapeutic use ; Humans ; Hypercholesterolemia/drug therapy ; Lactones/administration & dosage/pharmacology/therapeutic use ; Obesity/drug therapy ; Weight Loss
[en] Orlistat (tetrahydrolipstatin), launched by Roche under the trade name Xenical, is a selective inhibitor of pancreatic and gastro-intestinal lipases. It reduces the digestion of dietary fat and its resorption through digestive mucosa by around 30%. It is indicated, at a dose of 3 x 120 mg/day (one dose with each meal) and together with a moderately low-calorie and low-fat diet, for the treatment of obesity. It has been shown, in placebo-controlled two-year trials, to almost double the number of obese subjects who succeed in loosing at least 10% of initial body weight. Independently, it contributes to decrease serum cholesterol levels by 6-10%. Because of its mechanism of action, this drug can induce intestinal side-effects which tend to decrease with time and with the reduction of fat intake, thus improving diet compliance.

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.